Biotech focuses on infusing biological processes with technology to improve human, animal, and environmental health. Biotech & Pharma businesses utilize technology to work toward disease prevention, treatment and cure. These businesses also work in Agtech and fuel development. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| BillionToOne | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $396.39MM | Series D | 6/21/2024 | $130.47MM | $1.25B | $28.02 | Premji Invest, Neuberger Berman, Adams Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, Fifty Years | |||||
| Pendulum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $121.76MM | Series C | 6/30/2023 | $64MM | $308.05MM | $3.24 | Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, Fonterra | |||||
| Terray Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $201.97MM | Series B | 10/17/2024 | $120MM | $386.49MM | $6.66 | Bedford Ridge Capital, NVIDIA, Maverick Capital, Goldcrest Capital, Madrona Venture Group, Two Sigma Ventures, XTX Ventures, Digitalis Ventures, Alexandria Venture Investments | |||||
| Triveni Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $297.49MM | Series C | 6/17/2026 | $65.25MM | $423.44MM | $1.26 | Ascenta Capital, Janus Henderson Investors, Deep Track Capital, OrbiMed, Atlas Venture, Viking Global Investors | |||||
| Biolinq | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $275.18MM | Series C-1 | 4/22/2025 | $100MM | $397.31MM | $1.05 | Alpha Wave Ventures, RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, Features Capital | |||||
| CG Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $510.76MM | Series F | 8/2/2023 | $105.02MM | $615.24MM | $1.29 | Foresite Capital, TCGX, Avidity Partners, BVF Partners, Janus Henderson Investors, Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporatoin, RA Capital Management | |||||
| Frontier Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $255.5MM | Series C | 6/25/2024 | $100MM | $438.18MM | $2.34 | Deerfield Management Company, Droia Ventures, Galapagos NV, DCVC, MPM Capital, RA Capital Management, Deep Track Capital, ArrowMark Partners | |||||
| Juvenescence | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Unlearn | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $135.17MM | Series C | 2/8/2024 | $50MM | $368.17MM | $9.24 | Altimeter Capital Management, Radical Ventures, Mubadala Capital, Wittington Ventures, EPIC Ventures, Necessary Ventures, Insight Partners, 8VC, DCVC | |||||
| Seaport Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $330.1MM | Series B | 10/21/2024 | $226MM | $725.46MM | $14.92 | General Atlantic, T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs, CPP Investments, ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, PureTech Health | |||||
| Tessera Therapeutics | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $587.85MM | Series D | 12/1/2025 | $200MM | $668.33MM | $5.18 | Bill & Melinda Gates Foundation, Regeneron | |||||
| Umoja Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $373.84MM | Series C | 1/14/2025 | $100MM | $422.45MM | $3.95 | Double Point Ventures, DCVC Bio, ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank, CaaS Capital, Emerson Collective, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota | |||||
| Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $262MM | Series B | 3/1/2023 | $135MM | $450.56MM | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | |||||
| Cour Pharmaceuticals Development | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Ginkgo Bioworks | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $785.53MM | Series E | 5/28/2020 | $360MM | $4.89B | $150.19 | T. Rowe Price, Allen & Company, Baillie Gifford, Cascade Investment, General Atlantic, Reshape Holdings, Viking Global Investors, Illumina | |||||
| Kailera Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $959.96MM | Series B | 10/14/2025 | $603.18MM | $1.4B | $14.00 | Bain Capital, Adage Capital Management, Canada Pension Plan Investment Board, Invus, Janus Henderson Investors, Perseverance Capital, QIA, Royalty Pharma, Surveyor Capital, T. Rowe Price, Atlas Venture, Bain Capital Life Sciences, RTW Investments, Sirona Capital | |||||
| Neurona Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $342.29MM | Series F | 4/3/2025 | $101.71MM | $578.63MM | $2.06 | Fidelity, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, Spur Capital Partners | |||||
| Apogee Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Arthrosi Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $294.54MM | Series E | 10/8/2025 | $148.1MM | $385.03MM | $6.54 | Prime Eight Capital, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech | |||||
| Cellarity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $435.63MM | Series D | 12/23/2024 | $196.06MM | $517.83MM | $3.60 | Undisclosed Investors | |||||
| Kriya Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $940.5MM | Series D | 9/10/2025 | $320.82MM | $1.67B | $10.34 | Patient Square Capital, Premji Invest, Peter Thiel, Narya Capital, The T1D Fund | |||||
| LetsGetChecked | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Resilience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $4.18B | Series D | 6/6/2022 | $625MM | $8.84B | $60.73 | Undisclosed Investors | |||||
| Cerapedics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $163.58MM | Series G | 6/5/2024 | $15.23MM | $744.31MM | $5.64 | Undisclosed Investors | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.